Inovio Pharmaceuticals Inc
INO1.455USD
+0.025+1.75%
交易中 （美東）報價延遲15分鐘
53.36M總市值
虧損本益比TTM
關於 Inovio Pharmaceuticals Inc 公司
Inovio Pharmaceuticals, Inc. 是一家臨牀階段的生物技術公司。該公司專注於開發和商業化脫氧核糖核酸 (DNA) 藥物，以幫助治療和預防與人乳頭瘤病毒 (HPV)、癌症和傳染病相關的疾病。其 DNA 藥物管線包括用於治療 HPV 相關複發性呼吸道乳頭狀瘤病 (RRP) 的 INO-3107；用於治療 HPV 相關口咽鱗狀細胞癌 (OPSCC) 的 INO-3112；用於治療肛門或肛周 HSIL 的 VGX-3100；用於治療多形性膠質母細胞瘤 (GBM) 的 INO-5401，以及用於治療多形性膠質母細胞瘤 (GBM) 的 INO-5401。其主要候選藥物是用於治療 RRP 的 INO-3107，RRP 是一種由 HPV 感染引起的罕見且使人衰弱的呼吸道疾病。該公司的 DNA 藥物平臺由 DNA 質粒和 CELLECTRA 設備組成，後者用於將 DNA 質粒輸送到細胞中。該公司的 CELLECTRA 設備組合包括兩種型號。
公司簡介
公司代碼INO
公司名稱Inovio Pharmaceuticals Inc
上市日期Dec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
員工數量134
證券類型Ordinary Share
年結日Dec 08
公司地址660 W. Germantown Pike
城市PLYMOUTH MEETING
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編19462
電話18584103134
網址https://www.inovio.com/
公司代碼INO
上市日期Dec 08, 1998
CEODr. Jacqueline Elizabeth Shea, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
+32.11%
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
+33.04%
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
收入明細
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
65.34K
0.00%
業務
地區
暫無數據
股東統計
更新時間: 7月27日 週日
更新時間: 7月27日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Deep Track Capital LP
6.12%
BlackRock Institutional Trust Company, N.A.
4.22%
The Vanguard Group, Inc.
3.98%
BofA Global Research (US)
2.56%
Geode Capital Management, L.L.C.
1.66%
Other
81.45%
持股股東
持股股東
佔比
Deep Track Capital LP
6.12%
BlackRock Institutional Trust Company, N.A.
4.22%
The Vanguard Group, Inc.
3.98%
BofA Global Research (US)
2.56%
Geode Capital Management, L.L.C.
1.66%
Other
81.45%
股東類型
持股股東
佔比
Investment Advisor
10.80%
Hedge Fund
6.99%
Investment Advisor/Hedge Fund
5.77%
Research Firm
3.06%
Individual Investor
0.56%
Bank and Trust
0.30%
Venture Capital
0.13%
Pension Fund
0.02%
Other
72.36%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
302
14.08M
27.64%
-1.14M
2025Q1
358
13.94M
38.02%
-1.87M
2024Q4
376
13.66M
38.08%
+2.74M
2024Q3
379
8.99M
34.33%
-1.39M
2024Q2
391
8.36M
32.11%
+1.80M
2024Q1
412
4.61M
19.75%
-2.01M
2023Q4
431
4.68M
20.64%
-2.86M
2023Q3
449
5.16M
23.15%
-3.37M
2023Q2
462
6.56M
29.43%
-5.01M
2023Q1
491
10.80M
49.36%
-1.98M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Deep Track Capital LP
3.12M
6.12%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.15M
4.22%
+393.45K
+22.37%
Mar 31, 2025
The Vanguard Group, Inc.
2.03M
3.98%
+355.37K
+21.23%
Mar 31, 2025
BofA Global Research (US)
1.30M
2.56%
+664.00K
+103.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
846.80K
1.66%
+218.30K
+34.73%
Mar 31, 2025
Stonepine Capital Management, LLC
518.33K
1.02%
-531.67K
-50.64%
Mar 31, 2025
State Street Global Advisors (US)
514.15K
1.01%
+9.84K
+1.95%
Mar 31, 2025
Northern Trust Investments, Inc.
461.70K
0.91%
+242.90K
+111.02%
Mar 31, 2025
Susquehanna International Group, LLP
194.37K
0.38%
+152.20K
+360.91%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 3000 ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
DFA Dimensional US Core Equity Market ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.01%
iShares Russell 3000 ETF
佔比0%
Invesco RAFI US 1500 Small-Mid ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
iShares Biotechnology ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
公告日期
類型
比率
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
